Q-omics provides the consensus-scored SCRT1 profile across patient tissues and cancer cell-line models. SCRT1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SCRT1 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, SCRT1 RNA expression shows 14,958 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, and GBM as cancer lineages where SCRT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCRT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCRT1 survival associations across molecular data types. SCRT1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCRT1 RNA expression–survival associations across cancer types. High SCRT1 expression shows unfavorable associations in LIHC and LUSC, but favorable associations in LGG, UVM, PAAD and THYM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SCRT1 RNA expression.
This table summarizes SCRT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for SCRT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCRT1 shows lower tumor expression in KIRC and KICH and higher tumor expression in LIHC, BRCA, LUSC and STAD. The LIHC box plot shows higher SCRT1 RNA expression in tumor versus normal tissue (log2 FC = +0.044, t-test p < 0.001).
This table shows molecular features associated with SCRT1 in patient tissues and cancer cell lines. In patient samples, SCRT1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SCRT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
